Lorlatinib/lorlatinib drug price analysis in 2024

Lorlatinib Lorlatinib is a targeted therapy drug for non-small cell lung cancer (NSCLC), especially suitable for advanced patients with ALK (anaplastic lymphoma kinase)-positive disease. When the ALK gene in cancer cells mutates, resulting in abnormal ALK protein, lorlatinib can control the division and growth of cancer cells by inhibiting this abnormal ALK activity.

For patients who have not been treated with other ALK tyrosine kinase inhibitors (TKIs), lorlatinib can be used as a first-line treatment; for those patients whose condition worsens despite receiving other ALK TKIs, lorlatinib also shows its unique therapeutic effect.

In the domestic market, lorlatinib has been launched in different specifications and has been included in the scope of medical insurance, bringing good news to the majority of patients. Common drug specifications include 90 tablets of 25mg and 30 tablets of 100mg. For the domestic original version of lorlatinib, the price per box is roughly between 10,000 and 20,000 yuan. In Hong Kong, due to the impact of exchange rates and other factors, the price of each box may fluctuate between 30,000 and 50,000 yuan.

It is worth noting that there are also more affordable versions of generic drugs in overseas markets. These generic drugs are basically the same as the original drugs in terms of ingredients, but the price is significantly lower. Taking lorlatinib produced by a pharmaceutical factory in Laos as an example, the price of a box of 100mg*30 tablets may be only about 3,000 yuan (the price may fluctuate due to exchange rates).

Overall, lorlatinib, as a highly effective targeted therapy drug, provides a new treatment option for patients with non-small cell lung cancer. Its different prices in domestic and foreign markets also provide patients with more choices for purchasing drugs.